Del(1Fcgr2b-Fcgr3)1Vlcg
Allele Detail
|
Symbol: |
Del(1Fcgr2b-Fcgr3)1Vlcg |
Name: |
deletion, Chr 1, Regeneron Pharmaceuticals; deletion, Chr 1, Velocigene |
MGI ID: |
MGI:5468708 |
Synonyms: |
FcgRI-only |
Gene: |
Del(1Fcgr2b-Fcgr3)1Vlcg Location: Chr1:170788127-170892504 bp Genetic Position: Chr1, Syntenic
|
|
Strain of Origin: |
Not Specified
|
|
Allele Type: |
|
Not Specified |
Mutations: |
|
Intergenic deletion, Intragenic deletion
|
|
|
Del(1Fcgr2b-Fcgr3)1Vlcg involves 13 genes/genome features (Fcgr2b, Gm10522, Fcgr4 ...)
View all
|
|
|
Mutation details: Mice deficient for Fcgr2b, Fcgr3, and Fcgr4 were generated by deletion of the low affinity Fcgr locus using Velocigene technology.
(J:190859)
|
|
|
Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available
|
Carrying any Del(1Fcgr2b-Fcgr3)1Vlcg Mutation: |
0 strains or lines available
|
|
Original: |
J:190859 Albanesi M, et al., Cutting Edge: FcgammaRIII (CD16) and FcgammaRI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma. J Immunol. 2012 Dec 15;189(12):5513-7 |
All: |
1 reference(s) |
|